Chemopreventive Effects of the Standardized Extract (DA-9601) of Artemisia asiatica on Azoxymethane-Initiated and Dextran Sulfate Sodium-Promoted Mouse Colon Carcinogenesis

Authors: Kim, Hyun Soo1; Kundu, Joydeb Kumar1; Lee, Jeong-Sang1; Oh, Tae-Young2; Na, Hye-Kyung1; Surh, Young-Joon1

Source: Nutrition and Cancer, Volume 60, Supplement 1, 2008 , pp. 90-97(8)

Publisher: Routledge, part of the Taylor & Francis Group

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Dextran sulfate sodium (DSS) administration has been reported to cause inflammation in mouse colonic mucosa, which promotes colon carcinogenesis. When male ICR mice were treated with a single intraperitoneal dose (10 mg/kg body weight) of azoxymethane (AOM) followed by 2.5% DSS in drinking water for 7 consecutive days, all developed tumors at the 16th wk, mostly in the distal colon. Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) were markedly upregulated in the AOM-initiated and DSS-promoted colon tumors. The DNA binding activity of nuclear factor-kappaB (NF-κ B) was also elevated in the colon tumors. In this study, we examined the chemopreventive effects of the standardized extract (DA-9601) of Artemisia asiatica that has been used in the traditional herbal medicine for the treatment of inflammatory disorders. Mice fed the chow diet containing 10% DA-9601 for 15 wk following DSS treatment displayed the significantly lower multiplicity of colon tumors. DA-9601 treatment suppressed the expression of COX-2 and iNOS as well as NF-κ B DNA binding in the colonic tissues. It also downregulated the phosphorylation of extracellular, signal-regulated protein kinase and p38 mitogen-activated protein kinase that are upstream of NF-κ B. Furthermore, DA-9601 reduced expression of β-catenin in colonic mucosa of mice challenged with AOM plus DSS.

Document Type: Research article

DOI: 10.1080/01635580802404170

Affiliations: 1: Seoul National University, Seoul, South Korea 2: Dong-A Pharmaceutical Co. Ltd., Yongin-Si, Kyunggi-do, South Korea

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A